Sorafenib Tablet, Film Coated
Product Images NDC 24979-715

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sorafenib (NDC 24979-715). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Label 120s)

FDA Label Image

Fig 1 (Fig1)

This is a comparison of the efficacy of Sorafenib versus Placebo in patients. The study involved a total of 602 patients, with 299 patients receiving Sorafenib and 303 receiving Placebo. The median time for survival in the Sorafenib group was 10.7 months, while the median time for survival in the Placebo group was 7.9 months, with a hazard ratio of 0.69 and p-value of 0.00058. The graph shows the number of patients at risk over the course of the study, which lasted up to 18 months.*

FDA Label Image

Fig 3 (Fig3)

FDA Label Image

Image Description (Label 60s)

FDA Label Image

Image Description (Logo1)

FDA Label Image

Structural Formula (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.